Accuray Radixact System Receives Japanese Shonin Approval

Accuray Incorporated has received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market its Radixact Treatment Delivery System, Accuray Precision Treatment Planning System and iDMS Data Management System. Together, the treatment delivery system and software solutions enable clinicians to provide highly precise treatment, efficiently, for a wider range of cancer patients, including those undergoing retreatment. This new Radixact platform is now available in Japan, in certain markets in the European Union, and in the U.S. market.
 
“The Accuray team strives to provide our customers with innovative products that enhance the quality of patient care. With the introduction of the Radixact System, we are demonstrating significant progress in fulfilling on this promise,” said Juki Hozumi, president and general manager of Japan at Accuray. “This new, mainstream System enables clinicians to deliver the highly sculpted doses for precise, customized treatments the previous TomoTherapy platform was known for, faster, enabling the treatment of more patients every day. It also provides a foundation for future innovation.”
 
The Radixact System was designed to be an easy-to-operate, highly reliable, advanced radiation therapy device. The System features a more powerful linear accelerator, low-dose fan beam MVCT imaging and unique helical treatment mode, so that clinicians can deliver highly accurate, individualized dose distributions to any tumor. The fully-integrated, simplified adaptive treatment planning solution enables clinicians to routinely adjust treatment plans during the course of treatment to account for changes in tumor size, shape and location, thereby increasing treatment precision.
 
“The approval of the Radixact System represents a key milestone in our strategic growth plans for the Japanese market,” said Joshua H. Levine, president and CEO of Accuray. “We are seeing positive momentum in the adoption of the Radixact System as clinicians become aware of its benefits. Feedback from a number of early customers indicates the System enables them to deliver precise radiation therapy, to more patients, in considerably less time than has been possible with the TomoTherapy System.”
 
Accuray Incorporated is a radiation oncology company that develops, manufactures and sells tumor treatment solutions. The Sunnyvale, Calif.-based company’s technologies deliver the full range of radiation therapy and radiosurgery treatments.